Printer Friendly

Articles from M2 Pharma (August 1, 2018)

1-26 out of 26 article(s)
Title Author Type Words
10x Genomics Partners with BioLegend and Immudex to Extend Research Applications of Its New Single Cell Feature Barcoding Technology. 471
180 Therapeutics Touts Positive Results from a Phase 2a Clinical Trial of Anti-TNF Therapy in Dupuytren's Disease. 573
Active Biotech updates on clinical development of laquinimod in Huntington's disease. 244
Amgen announces breaking ground of new biomanufacturing plant at Rhode Island campus. 154
Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug. 607
BioSig Technologies applies for Nasdaq listing. 217
Daiichi Sankyo signs exclusive worldwide licensing agreement with Glycotope. 170
Eli Lilly and Dana-Farber Cancer Institute extend cancer research collaboration. 161
Elstar Therapeutics Vessey, Hastewell to Board of Directors. 474
FDA Grants Breakthrough Therapy Designation for Lenvima/Keytruda Combination as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma. 756
GE Healthcare, Lantheus Start Phase 3 Clinical Trial of Investigational Agent for the Detection of Coronary Artery Disease. 438
I-Mab Biopharma elects Jielun Zhu as new CFO. 112
I-Mab Biopharma names Jielun Zhu new chief financial officer. 279
Laekna to develop and commercialise two oral Akt inhibitors with positive proof-of-concept results. 218
LenioBio GmbH and Fraunhofer IME enter into exclusive licence agreement. 174
Medigus signs US distribution deal for MUSE system. 189
MerLion Regains North American Rights to XTOROTM FDA-Approved Antibiotic for Treatment of Ear Infections. 268
Novocure Publishes Results of Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer. Clinical report 325
NuVasive achieves GAAP net income of USD11.5m for Q2 2018. 155
PatientWisdom Inc receives USD1m under Series A round of funding. 177
Pfizer Receives European Approval for Oncology Biosimilar, Trazimera. 244
Puma Biotechnology Files New Drug Submission for Nerlynx in Canada. 331
RedHill Biopharma achieves primary endpoint and key secondary endpoints in phase III study of RHB-104. 187
United Therapeutics wins US FDA approval of the implantable system for Remodulin (ISR) for treating PAH. 267
Verona Pharma begins Phase 2 clinical trial evaluating nebulised RPL554 as add-on therapy. 228
Zealand Pharma reports increase in Soliqua 100/33/ Suliqua royalty revenues in Q2 2018. Financial report 253

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters